| abstract |
The use of triclosan for treatment of gastrointestinal disorders associated with Helicobacter pylori infections is disclosed. The medicaments may be in the form of powders, granules, spheroids or liquids, or in unit dosage form as capsules or tablets containing 1 to 100mg, preferably 10 to 60mg, of triclosan. The medicaments may also be in gastric sustained release form as raft forming tablets or liquids, optionally to be co-administered with a solid pharmaceutically acceptable carboxylic acid or acid salt, or as muco-adherent-coated granules or spheroids. |